2023 Q1 Form 10-K Financial Statement
#000095017023008942 Filed on March 21, 2023
Income Statement
Concept | 2023 Q1 | 2022 Q4 | 2022 |
---|---|---|---|
Revenue | $810.4K | $796.4K | $2.509M |
YoY Change | 93.7% | 120.86% | 55.04% |
Cost Of Revenue | $50.59K | $190.1K | $370.4K |
YoY Change | 122.28% | 39.07% | 12.88% |
Gross Profit | $759.8K | $606.3K | $2.138M |
YoY Change | 92.06% | 170.8% | 65.76% |
Gross Profit Margin | 93.76% | 76.13% | 85.24% |
Selling, General & Admin | $2.848M | $2.289M | $9.624M |
YoY Change | 18.41% | 31.88% | 8.73% |
% of Gross Profit | 374.82% | 377.52% | 450.07% |
Research & Development | $66.99K | $27.21K | $300.8K |
YoY Change | 60.58% | -23.82% | -49.06% |
% of Gross Profit | 8.82% | 4.49% | 14.07% |
Depreciation & Amortization | |||
YoY Change | |||
% of Gross Profit | |||
Operating Expenses | $2.966M | $2.316M | $10.29M |
YoY Change | 20.08% | 30.76% | 5.37% |
Operating Profit | -$2.155M | -$1.710M | -$7.786M |
YoY Change | 5.07% | 10.5% | -4.48% |
Interest Expense | $123.3K | -$93.44K | $500.0K |
YoY Change | -200.65% | -25.25% | -0.01% |
% of Operating Profit | |||
Other Income/Expense, Net | -$87.96K | $0.00 | -$438.0K |
YoY Change | 13.38% | ||
Pretax Income | -$2.243M | -$1.803M | -$8.224M |
YoY Change | 3.19% | 7.82% | -3.68% |
Income Tax | |||
% Of Pretax Income | |||
Net Earnings | -$2.243M | -$1.803M | -$8.224M |
YoY Change | 3.19% | 7.82% | -3.68% |
Net Earnings / Revenue | -276.78% | -226.43% | -327.83% |
Basic Earnings Per Share | -$0.67 | -$2.62 | |
Diluted Earnings Per Share | -$0.67 | -$0.54 | -$2.62 |
COMMON SHARES | |||
Basic Shares Outstanding | 3.343M | 3.343M | 3.144M |
Diluted Shares Outstanding | 3.343M | 3.144M |
Balance Sheet
Concept | 2023 Q1 | 2022 Q4 | 2022 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $8.213M | $9.844M | $9.844M |
YoY Change | 6.64% | 7.64% | 7.64% |
Cash & Equivalents | $8.200M | $9.800M | $9.844M |
Short-Term Investments | |||
Other Short-Term Assets | $11.55K | $11.55K | $964.5K |
YoY Change | -98.16% | 0.0% | 3.12% |
Inventory | $364.9K | $289.4K | $289.4K |
Prepaid Expenses | $671.4K | $953.0K | |
Receivables | $687.3K | $624.8K | $624.8K |
Other Receivables | $0.00 | $0.00 | $0.00 |
Total Short-Term Assets | $9.948M | $11.72M | $11.72M |
YoY Change | 10.21% | 11.0% | 11.0% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $91.40K | $129.1K | $129.1K |
YoY Change | 938.37% | 938.37% | |
Goodwill | |||
YoY Change | |||
Intangibles | |||
YoY Change | |||
Long-Term Investments | |||
YoY Change | |||
Other Assets | |||
YoY Change | |||
Total Long-Term Assets | $91.40K | $129.1K | $129.1K |
YoY Change | 938.57% | 938.46% | |
TOTAL ASSETS | |||
Total Short-Term Assets | $9.948M | $11.72M | $11.72M |
Total Long-Term Assets | $91.40K | $129.1K | $129.1K |
Total Assets | $10.04M | $11.85M | $11.85M |
YoY Change | 11.22% | 12.09% | 12.09% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $1.186M | $934.3K | $934.3K |
YoY Change | 25.56% | 6.9% | 6.9% |
Accrued Expenses | $491.7K | $720.2K | $720.2K |
YoY Change | 19.27% | 35.45% | 35.45% |
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Long-Term Debt Due | |||
YoY Change | |||
Total Short-Term Liabilities | $1.678M | $1.655M | $1.655M |
YoY Change | 23.65% | 17.7% | 17.7% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $5.000M | $5.000M | $5.000M |
YoY Change | 0.0% | 0.0% | 0.0% |
Other Long-Term Liabilities | $1.236M | $1.112M | $1.112M |
YoY Change | 67.97% | 81.66% | 81.66% |
Total Long-Term Liabilities | $6.236M | $6.112M | $6.112M |
YoY Change | 8.72% | 8.91% | 8.91% |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $1.678M | $1.655M | $1.655M |
Total Long-Term Liabilities | $6.236M | $6.112M | $6.112M |
Total Liabilities | $7.913M | $7.767M | $7.767M |
YoY Change | 11.57% | 10.67% | 10.67% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$117.9M | -$115.6M | |
YoY Change | 7.66% | ||
Common Stock | $120.0M | $119.7M | |
YoY Change | 7.89% | ||
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $2.126M | $4.085M | $4.085M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $10.04M | $11.85M | $11.85M |
YoY Change | 11.22% | 12.09% | 12.09% |
Cashflow Statement
Concept | 2023 Q1 | 2022 Q4 | 2022 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$2.243M | -$1.803M | -$8.224M |
YoY Change | 3.19% | 7.82% | -3.68% |
Depreciation, Depletion And Amortization | |||
YoY Change | |||
Cash From Operating Activities | -$1.631M | -$2.506M | -$6.596M |
YoY Change | 0.98% | 25.49% | -46.6% |
INVESTING ACTIVITIES | |||
Capital Expenditures | |||
YoY Change | |||
Acquisitions | |||
YoY Change | |||
Other Investing Activities | |||
YoY Change | |||
Cash From Investing Activities | |||
YoY Change | |||
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | |||
YoY Change | |||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | 0.000 | 0.000 | 7.295M |
YoY Change | -100.0% | -45.68% | |
NET CHANGE | |||
Cash From Operating Activities | -1.631M | -2.506M | -6.596M |
Cash From Investing Activities | |||
Cash From Financing Activities | 0.000 | 0.000 | 7.295M |
Net Change In Cash | -1.631M | -2.506M | 699.0K |
YoY Change | 12.98% | 25.49% | -35.02% |
FREE CASH FLOW | |||
Cash From Operating Activities | -$1.631M | -$2.506M | -$6.596M |
Capital Expenditures | |||
Free Cash Flow | |||
YoY Change |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2022Q2 | dei |
Entity Public Float
EntityPublicFloat
|
10.6 | |
CY2023Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
3343070 | |
CY2021Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
CY2022Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
CY2021Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
CY2021Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2022Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2021Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
50000000 | |
CY2022Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
50000000 | |
CY2022Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
3343070 | |
CY2022Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
3343070 | |
CY2021Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
2721373 | |
CY2021Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
2721373 | |
CY2022Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
334 | |
CY2021Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
272 | |
CY2022Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
119731458 | |
CY2021Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
110977835 | |
CY2022Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-115647143 | |
CY2021Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-107423013 | |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
4084649 | |
CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
3555094 | |
CY2022Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
11851488 | |
CY2021Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
10573162 | |
CY2022 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
2508645 | |
CY2021 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
1618076 | |
CY2022 | evok |
Cost Of Goods Sold Expenses
CostOfGoodsSoldExpenses
|
370394 | |
CY2021 | evok |
Cost Of Goods Sold Expenses
CostOfGoodsSoldExpenses
|
328118 | |
CY2022 | us-gaap |
Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
|
300789 | |
CY2021 | us-gaap |
Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
|
590476 | |
CY2022 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
9623599 | |
CY2021 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
8851129 | |
CY2022 | us-gaap |
Operating Expenses
OperatingExpenses
|
10294782 | |
CY2021 | us-gaap |
Operating Expenses
OperatingExpenses
|
9769723 | |
CY2022 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-7786137 | |
CY2021 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-8151647 | |
CY2021 | evok |
Forgiveness Of Paycheck Protection Loan And Accrued Interest
ForgivenessOfPaycheckProtectionLoanAndAccruedInterest
|
105130 | |
CY2022 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
62007 | |
CY2021 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
8615 | |
CY2022 | us-gaap |
Interest Expense
InterestExpense
|
500000 | |
CY2022 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
CY2022 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | |
CY2022 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001403708 | |
CY2022 | dei |
Amendment Flag
AmendmentFlag
|
false | |
CY2022 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
CY2022Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
CY2022 | us-gaap |
Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
|
http://fasb.org/us-gaap/2022#ProductMember | |
CY2021Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
CY2022 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
CY2022Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
CY2021 | us-gaap |
Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
|
http://fasb.org/us-gaap/2022#ProductMember | |
CY2021Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
CY2022 | dei |
Document Type
DocumentType
|
10-K | |
CY2022 | dei |
Document Annual Report
DocumentAnnualReport
|
true | |
CY2022 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2022-12-31 | |
CY2022 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2022 | |
CY2022 | dei |
Document Transition Report
DocumentTransitionReport
|
false | |
CY2022 | dei |
Entity File Number
EntityFileNumber
|
001-36075 | |
CY2022 | dei |
Entity Registrant Name
EntityRegistrantName
|
Evoke Pharma, Inc. | |
CY2022 | dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | |
CY2022 | dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
20-8447886 | |
CY2022 | dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
420 Stevens Avenue | |
CY2022 | dei |
Entity Address Address Line2
EntityAddressAddressLine2
|
Suite 370 | |
CY2022 | dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Solana Beach | |
CY2022 | dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
CA | |
CY2022 | dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
92075 | |
CY2022 | dei |
City Area Code
CityAreaCode
|
858 | |
CY2022 | dei |
Local Phone Number
LocalPhoneNumber
|
345-1494 | |
CY2022 | dei |
Security12b Title
Security12bTitle
|
Common Stock, par value $0.0001 per share | |
CY2022 | dei |
Trading Symbol
TradingSymbol
|
EVOK | |
CY2022 | dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | |
CY2022 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | |
CY2022 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
CY2022 | dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | |
CY2022 | dei |
Entity Small Business
EntitySmallBusiness
|
true | |
CY2022 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | |
CY2022 | dei |
Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
|
false | |
CY2022 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
CY2021 | us-gaap |
Interest Expense
InterestExpense
|
500050 | |
CY2022 | dei |
Auditor Firm
AuditorFirmId
|
243 | |
CY2022 | dei |
Auditor Name
AuditorName
|
BDO USA, LLP | |
CY2022 | dei |
Auditor Location
AuditorLocation
|
San Diego, California | |
CY2022Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
9843699 | |
CY2021Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
9144710 | |
CY2022Q4 | us-gaap |
Receivables Net Current
ReceivablesNetCurrent
|
624832 | |
CY2021Q4 | us-gaap |
Receivables Net Current
ReceivablesNetCurrent
|
295193 | |
CY2022Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
952954 | |
CY2021Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
923746 | |
CY2022Q4 | us-gaap |
Inventory Net
InventoryNet
|
289378 | |
CY2021Q4 | us-gaap |
Inventory Net
InventoryNet
|
185534 | |
CY2022Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
11551 | |
CY2021Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
11551 | |
CY2022Q4 | us-gaap |
Assets Current
AssetsCurrent
|
11722414 | |
CY2021Q4 | us-gaap |
Assets Current
AssetsCurrent
|
10560734 | |
CY2022Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
129074 | |
CY2021Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
12428 | |
CY2022Q4 | us-gaap |
Assets
Assets
|
11851488 | |
CY2021Q4 | us-gaap |
Assets
Assets
|
10573162 | |
CY2022Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
934312 | |
CY2021Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
874028 | |
CY2022Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
591158 | |
CY2021Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
519317 | |
CY2022Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
129074 | |
CY2021Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
12428 | |
CY2022Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
1654544 | |
CY2021Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
1405773 | |
CY2022Q4 | us-gaap |
Long Term Notes Payable
LongTermNotesPayable
|
5000000 | |
CY2021Q4 | us-gaap |
Long Term Notes Payable
LongTermNotesPayable
|
5000000 | |
CY2022Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
|
1112295 | |
CY2021Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
|
612295 | |
CY2022Q4 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
6112295 | |
CY2021Q4 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
5612295 | |
CY2022Q4 | us-gaap |
Liabilities
Liabilities
|
7766839 | |
CY2021Q4 | us-gaap |
Liabilities
Liabilities
|
7018068 | |
CY2022Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
CY2021Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
CY2022Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | |
CY2021Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | |
CY2022Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
CY2022 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-437993 | |
CY2021 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-386305 | |
CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-8224130 | |
CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-8537952 | |
CY2022 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-2.62 | |
CY2022 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-2.62 | |
CY2021 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-3.18 | |
CY2021 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-3.18 | |
CY2022 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
3143626 | |
CY2022 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
3143626 | |
CY2021 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
2682145 | |
CY2021 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
2682145 | |
CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-3214623 | |
CY2021 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1878954 | |
CY2021 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
1304846 | |
CY2021 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
13070154 | |
CY2021 | evok |
Issuance Of Common Stock From Stock Option Exercise Value
IssuanceOfCommonStockFromStockOptionExerciseValue
|
45454 | |
CY2021 | evok |
Payment Of At Market Offering Costs
PaymentOfAtMarketOfferingCosts
|
6421 | |
CY2021 | evok |
Issuance Of Common Stock From At The Market Offerings Value
IssuanceOfCommonStockFromAtTheMarketOfferingsValue
|
313107 | |
CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-8537952 | |
CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
3555094 | |
CY2022 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1458709 | |
CY2022 | evok |
Payment Of At Market Offering Costs
PaymentOfAtMarketOfferingCosts
|
148993 | |
CY2022 | evok |
Issuance Of Common Stock From At The Market Offerings Value
IssuanceOfCommonStockFromAtTheMarketOfferingsValue
|
7294976 | |
CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-8224130 | |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
4084649 | |
CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-8224130 | |
CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-8537952 | |
CY2021 | us-gaap |
Inventory Write Down
InventoryWriteDown
|
30000 | |
CY2021 | evok |
Forgiveness Of Paycheck Protection Loan And Accrued Interest1
ForgivenessOfPaycheckProtectionLoanAndAccruedInterest1
|
-105130 | |
CY2022 | evok |
Non Cash Lease Expense
NonCashLeaseExpense
|
37025 | |
CY2022 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1458709 | |
CY2021 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1878954 | |
CY2022 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
329639 | |
CY2021 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
271882 | |
CY2022 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
29208 | |
CY2021 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-157593 | |
CY2022 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
103843 | |
CY2021 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-20946 | |
CY2022 | evok |
Increase Decrease In Accounts Payable And Other Current Liabilities
IncreaseDecreaseInAccountsPayableAndOtherCurrentLiabilities
|
60284 | |
CY2021 | evok |
Increase Decrease In Accounts Payable And Other Current Liabilities
IncreaseDecreaseInAccountsPayableAndOtherCurrentLiabilities
|
-527859 | |
CY2022 | evok |
Accrued Compensation
AccruedCompensation
|
-71840 | |
CY2021 | evok |
Accrued Compensation
AccruedCompensation
|
496915 | |
CY2022 | evok |
Accrued Interest Expense
AccruedInterestExpense
|
500000 | |
CY2021 | evok |
Accrued Interest Expense
AccruedInterestExpense
|
499301 | |
CY2022 | us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-37025 | |
CY2021 | evok |
Milestone Payment
MilestonePayment
|
-5000000 | |
CY2022 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-6595987 | |
CY2021 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-12352944 | |
CY2021 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
14375000 | |
CY2021 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
1304846 | |
CY2022 | evok |
Proceeds From Issuance Of Common Stock At Market Offering
ProceedsFromIssuanceOfCommonStockAtMarketOffering
|
7443969 | |
CY2021 | evok |
Proceeds From Issuance Of Common Stock At Market Offering
ProceedsFromIssuanceOfCommonStockAtMarketOffering
|
319528 | |
CY2022 | evok |
Payment Of At Market Offering Costs
PaymentOfAtMarketOfferingCosts
|
148993 | |
CY2021 | evok |
Payment Of At Market Offering Costs
PaymentOfAtMarketOfferingCosts
|
6421 | |
CY2021 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
45454 | |
CY2022 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
7294976 | |
CY2021 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
13428715 | |
CY2022 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
698989 | |
CY2021 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
1075771 | |
CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
9144710 | |
CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
8068939 | |
CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
9843699 | |
CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
9144710 | |
CY2021 | us-gaap |
Loans Assumed1
LoansAssumed1
|
105130 | |
CY2022 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
153671 | |
CY2022 | evok |
Entity Incorporation Month And Year Of Incorporation
EntityIncorporationMonthAndYearOfIncorporation
|
2007-01 | |
CY2022Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
9800000 | |
CY2022Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
1.00 | |
CY2022Q2 | us-gaap |
Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
|
1-for-12 reverse stock split | |
CY2022Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
1.00 | |
CY2022 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p> | |
CY2022 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | |
CY2022 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Concentrations of Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Financial instruments that potentially subject the Company to significant credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in a federally insured financial institution in excess of federally insured limits. The Company has established guidelines designed to maintain safety and liquidity, has not experienced any losses in such accounts and believes the exposure to significant risk to the cash balance is minimal.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company relies on contract research organizations (“CROs”) and consultants to assist with ongoing regulatory activities. If the CROs and consultants are unable to continue their support, this could adversely affect the Company’s operations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">In addition, the Company relies on third-party manufacturers for the production of Gimoti. If the third-party manufacturers are unable to continue manufacturing Gimoti, or if the Company loses one of its sole source suppliers used in its manufacturing processes, the Company may not be able to meet any development needs or commercial supply demand for Gimoti, and the development and/or commercialization of Gimoti could be materially and adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company also relies on a dedicated third-party sales team to sell Gimoti. If such third-party organization is unable to continue serving as a dedicated sales team, the commercialization of Gimoti could be materially and adversely affected.</span></p> | |
CY2021Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
0 | |
CY2022Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
0 | |
CY2021 | evok |
Bad Debt Expense
BadDebtExpense
|
0 | |
CY2022 | evok |
Bad Debt Expense
BadDebtExpense
|
0 | |
CY2022Q4 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
239000 | |
CY2021Q4 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
150000 | |
CY2022Q4 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
50000 | |
CY2021Q4 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
35000 | |
CY2021Q4 | us-gaap |
Inventory Valuation Reserves
InventoryValuationReserves
|
30000 | |
CY2022 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
491851 | |
CY2021 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
557760 | |
CY2022 | evok |
Lease Commencement Date
LeaseCommencementDate
|
2017-01-01 | |
CY2022 | us-gaap |
Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
|
true | |
CY2022 | us-gaap |
Lease Expiration Date1
LeaseExpirationDate1
|
2023-10-31 | |
CY2022 | evok |
Operating Lease Incremental Borrowing Rate
OperatingLeaseIncrementalBorrowingRate
|
0.10 | |
CY2021 | evok |
Operating Lease Incremental Borrowing Rate
OperatingLeaseIncrementalBorrowingRate
|
0.10 | |
CY2022 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
39000 | |
CY2021 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
137000 | |
CY2021Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
134000 | |
CY2022Q4 | us-gaap |
Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
|
P0Y9M29D | |
CY2021Q4 | us-gaap |
Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
|
P0Y29D | |
CY2007Q2 | us-gaap |
Research And Development In Process
ResearchAndDevelopmentInProcess
|
650000 | |
CY2022Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | |
CY2022Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
CY2021Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
CY2022Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
CY2022Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
3343070 | |
CY2022 | us-gaap |
Common Stock Voting Rights
CommonStockVotingRights
|
Each share of common stock is entitled to one vote. The holders of the common stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors of the Company. | |
CY2022 | us-gaap |
Dividends Common Stock Cash
DividendsCommonStockCash
|
0 | |
CY2021 | evok |
Issuance Of Common Stock From Warrant Exercise Shares
IssuanceOfCommonStockFromWarrantExerciseShares
|
0 | |
CY2021 | evok |
Class Of Warrant Or Right Number Of Securities Expired
ClassOfWarrantOrRightNumberOfSecuritiesExpired
|
13517 | |
CY2021Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
139972 | |
CY2022Q4 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
34.80 | |
CY2022 | evok |
Issuance Of Common Stock From Warrant Exercise Shares
IssuanceOfCommonStockFromWarrantExerciseShares
|
0 | |
CY2022 | evok |
Class Of Warrant Or Right Number Of Securities Expired
ClassOfWarrantOrRightNumberOfSecuritiesExpired
|
139972 | |
CY2022Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
0 | |
CY2018Q2 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
323869 | |
CY2018Q2 | evok |
Share Based Compensation Arrangement By Share Based Payment Award Expiration Month And Year
ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationMonthAndYear
|
2028-02 | |
CY2022 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
|
P10Y | |
CY2022 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
78247 | |
CY2021 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
140167 | |
CY2022 | evok |
Share Based Compensation Arrangements By Share Based Payment Award Options Outstanding Date Intrinsic Value
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingDateIntrinsicValue
|
2.68 | |
CY2022 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
4.86 | |
CY2021 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
23.16 | |
CY2018 | us-gaap |
Stock Issued During Period Shares Period Increase Decrease
StockIssuedDuringPeriodSharesPeriodIncreaseDecrease
|
60000 | |
CY2022Q4 | evok |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized For Employee Stock Purchase Plan
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedForEmployeeStockPurchasePlan
|
37048 | |
CY2021 | us-gaap |
Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
|
0 | |
CY2022 | us-gaap |
Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
|
0 | |
CY2022 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1458709 | |
CY2021 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1878954 | |
CY2022Q4 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
1800000 | |
CY2022 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P1Y | |
CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
491851 | |
CY2021Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
417788 | |
CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
146497 | |
CY2021Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
121974 | |
CY2021Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
139972 | |
CY2022Q4 | evok |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized For Employee Stock Purchase Plan
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedForEmployeeStockPurchasePlan
|
37048 | |
CY2021Q4 | evok |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized For Employee Stock Purchase Plan
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedForEmployeeStockPurchasePlan
|
28715 | |
CY2022Q4 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
675396 | |
CY2021Q4 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
708449 | |
CY2022 | evok |
Minimum Age Of Employee To Participate In Defined Benefit Plan
MinimumAgeOfEmployeeToParticipateInDefinedBenefitPlan
|
P21Y | |
CY2022 | us-gaap |
Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
|
0 | |
CY2021 | us-gaap |
Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
|
0 | |
CY2022 | us-gaap |
Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
|
0 | |
CY2021 | us-gaap |
Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
|
0 | |
CY2022Q4 | us-gaap |
Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
|
0 | |
CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.21 | |
CY2021 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.21 | |
CY2021 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-0.05 | |
CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.02 | |
CY2022 | evok |
Effective Income Tax Rate Reconciliation Operating Loss And Tax Credits Other
EffectiveIncomeTaxRateReconciliationOperatingLossAndTaxCreditsOther
|
0.24 | |
CY2021 | evok |
Effective Income Tax Rate Reconciliation Operating Loss And Tax Credits Other
EffectiveIncomeTaxRateReconciliationOperatingLossAndTaxCreditsOther
|
0.25 | |
CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
|
0.01 | |
CY2021 | evok |
Effective Income Tax Rate Reconciliation Deductible Expense Share Based Compensation And Other Permanent Items
EffectiveIncomeTaxRateReconciliationDeductibleExpenseShareBasedCompensationAndOtherPermanentItems
|
0.01 | |
CY2022 | evok |
Cumulative Minimum Change In Ownership Percentage For Limitation On Utilization Of Net Operating Loss Carry Forwards
CumulativeMinimumChangeInOwnershipPercentageForLimitationOnUtilizationOfNetOperatingLossCarryForwards
|
0.50 | |
CY2022 | evok |
Cumulative Change In Ownership Period
CumulativeChangeInOwnershipPeriod
|
P3Y | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
24500000 | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
3600000 | |
CY2021Q4 | us-gaap |
Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
|
543000 | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
1825000 | |
CY2021Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
1413000 | |
CY2022Q4 | us-gaap |
Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
|
125000 | |
CY2022Q4 | evok |
Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
|
29000 | |
CY2021Q4 | evok |
Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
|
3000 | |
CY2022Q4 | evok |
Deferred Tax Assets Tax Accruals And Other
DeferredTaxAssetsTaxAccrualsAndOther
|
136000 | |
CY2021Q4 | evok |
Deferred Tax Assets Tax Accruals And Other
DeferredTaxAssetsTaxAccrualsAndOther
|
110000 | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
2115000 | |
CY2021Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
2069000 | |
CY2022Q4 | evok |
Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
|
29000 | |
CY2021Q4 | evok |
Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
|
3000 | |
CY2022Q4 | us-gaap |
Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
|
29000 | |
CY2021Q4 | us-gaap |
Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
|
3000 | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
2086000 | |
CY2021Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
2066000 | |
CY2022 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
20000 | |
CY2021 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
444000 | |
CY2022 | evok |
Percentage Of Taxable Income Offset By Tax Losses
PercentageOfTaxableIncomeOffsetByTaxLosses
|
0.80 | |
CY2022 | us-gaap |
Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
|
0 | |
CY2021 | us-gaap |
Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
|
0 | |
CY2022Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
2000000.0 | |
CY2021Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
2000000.0 | |
CY2022Q4 | us-gaap |
Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
|
0 |